Sales & Marketing News | pharmaphorum

News

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

News

Trump claims comprehensive victory in US election

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the triple whammy of a Republican majority in the Senate, House of R

News

Wegovy romps ahead after key rival sees slowdown

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.

News

AZ shares weaken as China investigation rumours swirl

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest market, wiping around $14 billion off its value.

News

Rosacea case showing redness and inflammatory papules and pustules

Journey slips on FDA approval of rosacea therapy

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.

Sarepta pulls plug on Duchenne exon-skipping drug

Avid Bioservices to go private in $1.1bn private equity deal

Trump claims comprehensive victory in US election

Wegovy romps ahead after key rival sees slowdown

AZ shares weaken as China investigation rumours swirl

Journey slips on FDA approval of rosacea therapy

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks